Scholar Rock (NASDAQ:SRRK) Shares Climb 4.6% – What’s Next?

Scholar Rock Holding Corporation (NASDAQ:SRRK – Get Free Report) shares traded up 4.6% on Monday. The stock traded as high as $45.09 and last traded at $45.2110. Approximately 1,649,732 shares were traded during mid-day trading, an increase of 13% from the average daily volume of 1,460,310 shares. The stock had previously closed at $43.21.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. HC Wainwright boosted their target price on shares of Scholar Rock from $65.00 to $70.00 and gave the stock a “buy” rating in a research note on Tuesday, September 15th. Evercore reiterated an “outperform” rating and set a $72.00 target price on shares of Scholar Rock in a research report on Tuesday, September 15th. TD Cowen reissued a “buy” rating on shares of Scholar Rock in a research note on Monday, September 14th. Citigroup raised their price target on Scholar Rock from $60.00 to $74.00 and gave the company a “buy” rating in a report on Monday, September 14th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $70.00 target price on shares of Scholar Rock in a report on Monday, September 21st. Three analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $67.67.

Check Out Our Latest Research Report on SRRK

Scholar Rock Trading Up 3.1%

The business’s 50-day moving average price is $46.13 and its two-hundred day moving average price is $48.22. The company has a market capitalization of $5.43 billion, a P/E ratio of -13.26 and a beta of 0.78. The company has a debt-to-equity ratio of 1.16, a current ratio of 5.41 and a quick ratio of 5.40.

Scholar Rock (NASDAQ:SRRK – Get Free Report) last released its quarterly earnings data on Tuesday, November 10th. The company reported ($0.81) EPS for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.04. The firm had revenue of $0.57 million during the quarter, compared to the consensus estimate of $0.30 million. During the same quarter in the prior year, the company earned ($0.90) EPS. As a group, analysts forecast that Scholar Rock Holding Corporation will post -3.04 EPS for the current fiscal year.

Insider Activity

In other Scholar Rock news, Director Srinivas Akkaraju purchased 146,970 shares of the company’s stock in a transaction dated Monday, October 26th. The shares were bought at an average price of $41.59 per share, with a total value of $6,112,482.30. Following the completion of the transaction, the director directly owned 6,380,517 shares in the company, valued at $265,365,702.03. This trade represents a 2.36% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 10.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Scholar Rock

Several institutional investors and hedge funds have recently modified their holdings of the business. Modern Wealth Management LLC increased its stake in Scholar Rock by 764.5% during the 3rd quarter. Modern Wealth Management LLC now owns 52,075 shares of the company’s stock worth $2,516,000 after purchasing an additional 46,051 shares in the last quarter. Integral Health Asset Management LLC lifted its stake in Scholar Rock by 67.3% in the third quarter. Integral Health Asset Management LLC now owns 1,255,000 shares of the company’s stock valued at $60,642,000 after buying an additional 505,000 shares in the last quarter. Cetera Investment Advisers acquired a new position in shares of Scholar Rock in the third quarter valued at approximately $2,392,000. Pathstone Holdings LLC boosted its holdings in shares of Scholar Rock by 16.6% in the third quarter. Pathstone Holdings LLC now owns 33,560 shares of the company’s stock valued at $1,622,000 after buying an additional 4,776 shares during the period. Finally, Headlands Technologies LLC acquired a new position in shares of Scholar Rock in the third quarter valued at approximately $430,000. 91.08% of the stock is currently owned by institutional investors and hedge funds.

About Scholar Rock

(Get Free Report)

Scholar Rock is a biopharmaceutical company based in Cambridge, Massachusetts, that develops medicines targeting growth factors and signaling proteins involved in disease. Its research has focused on the transforming growth factor beta (TGF-β) superfamily, which plays roles in processes including muscle development and immune regulation. The company’s lead program has been apitegromab, a selective inhibitor of myostatin developed for spinal muscular atrophy (SMA). Scholar Rock has studied the medicine as a potential treatment alongside existing SMA therapies, with the goal of improving patients’ motor function.

See Also

Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.